MedTrace Logo

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

NCT05603013 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2022-11-02

No results posted yet for this study

Summary

This is an open-label, single-arm, Phase II investigator-initiated trial of vinorelbine metronomic chemotherapy combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for treatment of advanced refractory non-small cell lung cancer and breast cancer.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma Breast

Interventions

DRUG

Vinorelbine

Vinorelbine Tartrate Oral

RADIATION

Radiotherapy

hypofractionated radiotherapy

DRUG

PD-1/PD-L1 inhibitor

PD-1/PD-L1 inhibitor subcutaneous injection or intravenous injection

DRUG

GM-CSF

GM-CSF subcutaneous injection

DRUG

IL-2

IL-2 subcutaneous injection

Sponsors & Collaborators

  • Second Affiliated Hospital of Soochow University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-30
Primary Completion
2024-01-01
Completion
2024-10-17

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05603013 on ClinicalTrials.gov